KIMBERLY SALSMAN: Open Payments
NPI 1295407047 · COVINGTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$911 in 43 payments from 15 companies in 2025. Trend: 2023 $832 · 2024 $764 · 2025 $911
Food & beverage: $911
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $190 |
| Novo Nordisk Inc | 5 | $165 |
| Lilly USA, LLC | 10 | $136 |
| GlaxoSmithKline, LLC. | 5 | $94 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $93 |
| Abbott Laboratories | 2 | $39 |
| ABBVIE INC. | 2 | $35 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $35 |
| GENZYME CORPORATION | 1 | $23 |
| Verona Pharma, Inc. | 1 | $20 |
Products named: BREZTRI, Ozempic, MOUNJARO, TRELEGY ELLIPTA, Kerendia, FREESTYLE LIBRE, XIFAXAN, KISUNLA.
Industry payments across LA — which companies pay providers there.
